Guturu P, Cicalese L, Duchini A

Language: English
References: 12
Page: 326-329
PDF size: 67.73 Kb.

ABSTRACT

Background and aims. Despite effective vaccine available, hepatitis A remains a significant cause of morbidity and mortality worldwide including acute liver failure, transplantation and death. Vaccination rates for hepatitis A in the general population are low. Rates of hepatitis A vaccination in healthcare personnel (HCP) are unknown. We studied vaccination rate to hepatitis A in a cohort of HCP at a large US academic center. Material and methods. An anonymous survey was circulated between 499 HCP at-risk of hepatitis A exposure at our Institution. Results were corrected for non-response rate and compared with the general US population using the 2007 CDC-National Immunization Survey. Rate of hepatitis A vaccination was compared with Institutional rate of vaccination for the Influenza 2009-2010 season. Results. Rate of vaccination for hepatitis A in HCP was 28.8% (response rate 41.4%; 207/499), with 58.9% having completed the full series and 24.7% being tested for post-vaccination immunity. Acceptance rate among non-vaccinated subjects was 70.7%. HCP hepatitis A vaccination rate was statistically greater than the national general population (28.8 vs. 12.1%, p ≤ 0.031). A statistically significant greater vaccination rate was found among USborn responders vs. foreign-born HCP (34.3 vs. 19.3%, p = 0.0324). Vaccination for hepatitis A was statistically inferior to that of Influenza (28.8 vs. 90%; P = 0.01). Conclusions. HCP have statistically higher vaccination rate for hepatitis A than the general population, but overall protection remains suboptimal with vaccination rate below those for mandatory vaccines. Further studies to determine whether hepatitis A vaccine is cost-effective in HCP are recommended.

REFERENCES

1. Berge JJ, Drennan DP, Jacobs RJ, Jakins A, Meyerhoff AS, Stubblefield W, et al. The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology 2000; 31: 469-73.

2. Zhou FJ, Shefer A, Weinbaum C, McCauley M, Kong Y. Impact of hepatitis A vaccination on health care utilization in the United States, 1996-2004. Vaccine 2007; 25: 3581-7.

3. Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev 2006; 28: 101-11.

4. Chodick G, Ashkenazi S, Lerman Y. The risk of hepatitis A infection among healthcare workers: a review of reported outbreaks and sero-epidemiologic studies. J Hospital Infection 2006; 62: 414-20.

5. Fiore AE, Wasley A, Bell BP, (ACIP) ACoIP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-7): 1-23.

6. Practices ACoI. Recommended adult immunization schedule: United States, 2011. Ann Intern Med 2011; 154: 168-73.

7. Lu PJ, Euler GL, Hennessey KA, Weinbaum CM. Hepatitis A vaccination coverage among adults aged 18-49 years in the United States. Vaccine 2009; 27: 1301-5.

8. Lindley MC, Lorick SA, Spinner JR, Krull AR, Mootrey GT, Ahmed F, et al. Student Vaccination Requirements of U.S. Health Professional Schools: A Survey. Ann Internal Med 2011; 154: 391-W131.

9. (CDC) Cfdcap, Chaves SS DN, Santibanez T. Hepatitis A vaccination coverage among children aged 24-35 months - United States, 2006 and 2007. MMWR 2009; (25): 689-94 [Internet].

10. Di Giammarino L, Dienstag JL. Hepatitis A-The price of progress. New England J Medicine 2005; 353: 944-6.

11. Jacobs RJ, Gibson GA, Meyerhoff AS. Cost-effectiveness of hepatitis A-B vaccine versus hepatitis B vaccine for healthcare and public safety workers in the western United States. Infection Control and Hospital Epidemiology 2004; 25: 563-9.

12. Rajan E, Shattock AG, Fielding JF. Cost-effective analysis of hepatitis A prevention in Ireland. Am J Gastroenterol 2000; 95: 223-6.